Unicycive Therapeutics Q2 net loss narrows on warrant liability change
UNCY•NDA resubmission and commercial readiness
- Unicycive plans to resubmit its NDA for oxylanthanum carbonate (OLC) after a successful FDA inspection of its manufacturing vendor.
- The company continues commercial readiness initiatives ahead of a potential OLC launch.
- Unicycive aims to expand market awareness for OLC while awaiting regulatory progress.
Operating expenses rise on launch preparation
- Higher R&D and G&A expenses were driven by increased non-cash stock-based compensation and commercial launch preparation.
Quarterly loss narrows on warrant liability change
- US kidney disease biotech's Q2 net loss narrowed from the prior year.
- Net loss decline was attributed to a change in the fair value of warrant liability.
- Q2 loss per share was $0.06.
Related News
Acurx says Japan, Mexico patent offices grant new patents for DNA polymerase IIIC inhibitor antibiotics
ACXP•
Safe Pro Group enters CRADA with US Army ERDC on AI-driven situational intelligence using drone data
SPAI•
